



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/618,526
Filing Date	July 11, 2003
First Named Inventor	Fallaux et al.
Group Art Unit	1632 16 33
Examiner Name	D. Nguyen

Attorney Docket Number

2578-3833.9US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
SDP		#US- 5,707,818	01-1998	Ameniano et al.	
SDP		#US- 5,824,544	10-1998	Ameniano et al.	
Dupl.		#US- 6,040,174	03-2000	Indri et al.	
SDP		#US- 6,051,430	04-18-2000	Plasterk et al.	
SDP		#US- 6,140,103	10-31-2000	Einerhand et al.	
Dupl.		#US- 6,203,975	03-2001	Wilson	
SDP		#US- 6,204,052	03-20-2001	Bout et al.	
	✓	#US- 6,210,939	04-2001	Gregory et al.	
	✓	#US- 6,232,105	05-15-2001	Einerhand et al.	
	✓	#US- 6,238,893	05-29-2001	Hoeben et al.	
Dupl.		#US- 6,203,212	07-24-2001	Fallaux et al.	
SDP		#US- 6,306,652 B1	10-23-2001	Fallaux et al.	
	✓	#US- 2002/0102732 A1	08-01-2002	Fallaux et al.	
	✓	#US- 2002/0173039 A1	11-02-2002	Fallaux et al.	
	✓	#US- 2002/0164802 A1	11-07-2002	Fallaux et al.	
	✓	#US- 2003/0104626 A1	06-05-2003	Fallaux et al.	
		#US- 6,602,706 B1	08-05-2003	Fallaux et al.	
	✓	#US- 2004/0087027 A1	05-2004	Gregory et al.	
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² - Number ⁴ - Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
SDP		#EP 117060	08-1984	Levinson		
SDP		#WO 97/00326	01-03-1997	Introgen B.V.		

Examiner Signature

Seth D. Prich

Date Considered

8/19/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/618,526
<i>(use as many sheets as necessary)</i>		Filing Date	July 11, 2003
		First Named Inventor	Fallaux et al.
		Group Art Unit	1632
		Examiner Name	D. Nguyen
Sheet	1	of	1
		Attorney Docket Number	
		2578-3833.9JUS	

Examiner Signature	Scott D. Pritch	Date Considered	8/19/05
-----------------------	-----------------	--------------------	---------

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the Office in the following prior application:

Serial No.: 10/219,414

Case No. 02-1000

For: STOCKS OF REPLICATION DEFICIENT ADENOVIRUS, which application is being relied upon for an earlier filing date under 35 U.S.C. § 120

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

of

2

Complete if Known

Application Number	10/618,526
Filing Date	July 11, 2003
First Named Inventor	Fallaux et al.
Group Art Unit	1632-1633
Examiner Name	D. Nguyen

Attorney Docket Number 2578-3833 9US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SDP	✓	WHITE et al., Adenovirus E1B 19-Kilodalton Protein Overcomes the Cytotoxicity of E1A Proteins, Journal of Virology, June 1991, pp. 2968-78, Vol. 65, No. 6.	
	✓	WHITE et al., Role of Adenovirus E1B Proteins in Transformation: Altered Organization of Intermediate Filaments in Transformed Cells That Express the 19-Kilodalton Protein, Molecular and Cellular Biology, Jan. 1990, pp. 120-30, Vol. 10, No. 1.	
	✓	GenBank Accession No. X02996.1, 1993, "Adenovirus type 5 left 32% of the genome."	
	✓	WHITE et al., Specific disruption of intermediate filaments and the nuclear lamina by the 19-kDa product of the adenovirus E1B oncogene, Proc. Natl. Acad. Sci., December 1989, pp. 9886-90; Vol. 86.	
	✓	GALLIMORE et al., Transformation of Human Embryo Retinoblasts with Simian Virus 40, Adenovirus and ras Oncogenes, Anticancer Research, 1986, pp. 499-508, Vol. 6.	
	✓	HITT et al., Construction and Propagation of Human Adenovirus Vectors, Cell Biology, 1994, pp. 479-90, Vol. 1, Academic Press, San Diego, California.	
	✓	MITANI et al., Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector, Proc. Natl. Acad. Sci., April 1995, pp. 3854-58, Vol. 92.	
	✓	MARCK, CHRISTIAN, 'DNA Strider': a 'C' program for the fast analysis of DNA and protein sequences on the Apple Macintosh family of computers, Nucleic Acids Research, 1988, pp. 1829-36, Vol. 16, No. 5.	
	✓	PESHWA et al., Cultivation of Mammalian Cells as Aggregates in Bioreactors: Effect of Calcium Concentration on Spatial Distribution of Viability, 1993, pp. 179-87, Vol. 41.	
	✓	BERG et al., High-Level Expression of Secreted Proteins from Cells Adapted to Serum-Free Suspension Culture, BioTechniques 1993, pp. 972-78, Vol. 14, No. 6.	
	✓	WHITE et al., The 19-Kilodalton Adenovirus E1B Transforming Protein Inhibits Programmed Cell Death and Prevents Cytolysis by Tumor Necrosis Factor alpha, Molecular and Cellular Biology, June 1992, pp. 2570-80, Vol. 12, No. 6.	
✓	✓	COLBY et al., Adenovirus Type 5 Virions Can Be Assembled in Vivo in the Absence of Detectable Polypeptide IX, Journal of Virology, Sept. 1981, pp. 997-80, Vol. 39, No. 3.	

Examiner
Signature

Scott D. Pribe

Date
Considered

8/19/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number	10/618,526
Filing Date	July 11, 2003
First Named Inventor	Fallaux et al.
Group Art Unit	1632 / 633
Examiner Name	D. Nguyen

Attorney Docket Number 2578-3833.91US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SDP	✓	RULEY, H. EARL, Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture, Nature, August 1983, pp. 602-06, Vol. 304.	
	✓	GRAHAM et al., Size and location of the transforming region in human adenovirus type 5 DNA, Nature, October 25, 1974, pp. 687-91, Vol. 251.	
	✓	PRELICH et al., Functional Characterization of Thermolabile DNA-Binding Proteins That Affect Adenovirus DNA Replication, Journal of Virology, Mar. 1986, pp. 883-92, Vol. 57, No. 3.	
	✓	WOODWORTH et al., Transformation of Differentiated Rat Hepatocytes with Adenovirus and Adenovirus DNA, Journal of Virology, Nov. 1987, pp. 3570-79, Vol. 61, No. 11.	
	✓	RAO et al., The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins, Proc. Natl. Acad. Sci., August 1992, pp. 7742-46, Vol. 89.	
	✓	ROWE et al., Establishment and Characterization of Hamster Cell Lines Transformed by Restriction Endonuclease Fragments of Adenovirus 5, Journal of Virology, Jan. 1984, pp. 162-70, Vol. 49, No. 1.	
	✓	SAMBROOK et al., Molecular Cloning – A Laboratory Manual, 3rd edition, 2001, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, pp. 16.1 - 16.6.	
	✓	ACSADI et al., Adenovirus-mediated gene transfer into striated muscles, J Mol Med, 1995, pp. 165-80, Vol. 73.	
	✓	NCBI database excerpt: Locus AC_000008 (human adenovirus type 5)	
	✓	RHIM, JOHNG S., Development of Human Cell Lines from Multiple Organs, 2000, Annals New York Academy of Sciences, pp. 16-25.	
	✓	Notice of Opposition to a European Patent by Serono International S.A. filed against Patent No. 0 833 934.	
	✓	Opposition lodged by Cevac Pharmaceuticals GmbH against European Patent 0 833 934.	

Examiner
Signature

Scott D. Pribyl

Date
Considered

8/19/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.